Progress towards a vaccine for cervical cancer

Current Opinion in Obstetrics and Gynecology

Volumn 17, Issue 1, 2005, Pages 65-70

  Simon, Philippe ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Cervical cancer; Human papillomavirus infection; Vaccination

Indexed keywords

CANCER VACCINE; HPV 16 E7 VACCINE; MVA E2 VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; ZYC 101A;

CANCER SCREENING; CLINICAL PROTOCOL; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; WART VIRUS;

EID: 14644395542     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200502000-00012     Document Type: Review

References (40)

1. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364:249-256.
2. Singh GK, Miller BA, Hankey BF, Edwards BK. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage and survival, 1975-2000. Cancer 2004; 101:1051-1057.
3. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination [Review]. Nat Rev Immunol 2004; 4:46-54. This very interesting paper makes a perfect summary of HPV infection, immunity and vaccination.
4. Damin AP, Karam R, Zettler CG, et al. Evidence for an association of human papillomavirus and breast carcinomas. Breast Cancer Res Treat 2004; 84:131-137.
5. Rocha-Zavaleta L, Yescas G, Cruz RM, Cruz-Talonia F. Human papillomavirus infection and cervical ectopy. Int J Gynaecol Obstet 2004; 85:259-266. It was known that the preferential localization of dysplasia is the junction zone of the cervix. It now appears that the whole cervical ectopy carries such a risk.
6. Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 2004; 189:46-50. More than a well realized study, this paper presents a very high-risk population that every gynaecologist can be confronted with, and derives interesting results from its study.
7. Beby-Defaux A, Bourgoin A, Ragot S, et al. Human papillomavirus infection of the cervix uteri in women attending a health examination center of the French social security. J Med Virol 2004; 73:262-268. A description of the epidemiology of HPV infection in a low-risk population.
8. Bekkers RL, Massuger LF, Bulten J, Melchers WJ. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Rev Med Virol 2004; 14:95-105. This paper summarizes the knowledge about HPV, cervical dysplasia, its detection and the epidemiology of cervical cancer.
9. Calleja-Macias IE, Kalantari M, Huh J, et al. Genomic diversity of human papillomavirus-16, 18, 31 and 35 isolates in a Mexican population and relationship to European, African, and native American variants. Virology 2004; 319:315-323. An interesting paper discussing the different variants of HPV and their geographical origins.
10. Cuschieri KS, Cubie HA, Whitley MW, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004; 57:68-72. This very interesting paper stresses the high frequency of multiple high-risk HPV infections. This knowledge has major implications: the choice of potential vaccination (unipotent or multipotent?) and an understanding of the high risk of 'recurrences' of cervical dysplasia.
11. Pinto KR, Lu DW, Rader JS, Davila RM. Double cervix with bilateral and synchronous HSIL associated with different high-risk HPV types. A case report. Acta Cytol 2004; 48:273-277. A nice illustration of the high risk of multiple HPV type synchronous infection.
12. Baay MF, Smits E, Tjalma WA, et al. Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. Int J Cancer 2004; 108:258-261.
13. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003; 12:485-490.
14. Crum CP, Beach KJ, Hedley ML, et al. Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol. J Infect Dis 2004; 189:1348-1354. This article provides information about the clearance of HPV infections and the apparent 'regressions' of the cervical dysplasias.
15. Sellers JW, Karwalajtys TL, Kaczorowski J, et al. Survey of HPV in Ontario Women Group. Incidence, clearance and predictors of human papiliomavirus infection in women. Can Med Assoc J 2003; 168:421-425.
16. Molano M, Van den Brule A, Plummer M, et al. HPV Study Group. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158:486-494. This article provides interesting data about the natural clearance of HPV infection.
17. Xi LF, Demers GW, Koutsky LA, et al. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis 1995; 172:747-755.
18. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med 2003; 127:930-934.
19. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004; 190:37-45. This article provides interesting data about the natural clearance of the HPV infection and the influence of HIV co-infection.
20. Roden R, Wu TC. Preventative and therapeutic vaccines for cervical cancer. Expert Rev Vaccines 2003; 2:495-516. This very complete paper summarizes the immunological mechanisms implied during HPV infection and reviews the vaccines produced so far and their different types.
21. Abba MC, Laguens RM, Dulout FN, Golijow CD. The c-myc activation in cervical carcinomas and HPV 16 infections. Mutat Res 2004; 557:151-158. A correlation between HPV infection and the classical molecular biology of cancer.
22. Evans MF, Cooper K. Human papillomavirus integration: detection by in situ hybridization and potential clinical application. J Pathol 2004; 202:1-4. This paper comments on the consequences of infection by HPV and the consequences of its DNA integration.
23. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence - implications for cervical disease progression and monitoring. J Med Virol 2004; 73:65-70.
24. Ahn WS, Bae SM, Lee JM, et al. Searching for pathogenic gene functions to cervical cancer. Gynecol Oncol 2004; 93:41-48.
25. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995; 92:11553-11557.
26. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96:604-615. See Ref. [27].
27. Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003; 106:896-904. The above two articles [26,27] are a beautiful application of epidemiological statistics in the evaluation of the potential benefit of the introduction of an HPV preventive vaccine.
28. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9:48.
29. Pinto LA, Edwards J, Castle PE, et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 2003; 188:327-338.
30. Ohlschlager P, Osen W, Dell K, et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 2003; 77:4635-4645.
31. Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004; 13:110-116.
32. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651.
33. Corona Gutierrez CM, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004; 15:421-431. A description of a good clinical trial of therapeutic vaccination in patients presenting with cervical dysplasia.
34. Hallez S, Simon P, Maudoux F, et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepitheliai neopiasia. Cancer Immunol Immunother 2004; 53:642-650. This paper relates the immunological consequences of a therapeutic vaccination against HPV16.
35. Brandsma JL, Shlyankevich M, Zhang L, et al. Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papiliomas and infection. J Virol 2004; 78:116-1 23. A description of a therapeutic vaccine against E2 protein clinically active in the animal.
36. Baldwin PJ, van der Burg SH, Boswell CM, et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 2003; 9: 5205-5213. A description of a vaccination that displays a good clinical efficiency in humans.
37. Davidson EJ, Boswell CM, Sehr P, et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins Cancer Res 2003; 63:6032-6041. The same vaccine as in the preceding article that displays similar results.
38. Garcia F, Petry KU, Muderspach L, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004; 103:317-326.
39. Smyth LJ, Van Poelgeest MI, Davidson EJ, et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 2004; 10:2554-2961. This study shows how to improve the immunogenicity of a vaccination by a prime boost protocol of vaccination.
40. Biemelt S, Sonnewald U, Galmbacher P, et al. Product on of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 2003; 77:9211-9220. Vaccinating the entire population by eating potatoes or chewing tobacco. This paper describes some of the possibilities now offered by plant genetics and transgenic vegetables.